Stay informed about the new TrumpRx GLP-1 deal and corresponding pricing benchmarks before they begin influencing your pharmacy strategy in 2026.
In this 10-minute GLP-1 pricing update, Clinical Director Aya Desouki, PharmD, breaks down the Trump administration’s most favored nation type agreement with Eli Lilly and Novo Nordisk, new Medicare and Medicaid pricing, and how the upcoming TrumpRx direct-to-consumer channel could reset expectations for GLP-1 costs.
She explains why weight loss GLP-1 therapies are already the highest spend category for many plans, how highly variable coverage and strict utilization management play into today’s cost trends, and why employers and other stakeholders should expect renewed pressure from members as access expands.
In this video we also outline the growing 2026 pipeline, including oral GLP-1 therapies and new non-weight-loss indications that could significantly widen the eligible population. Aya explores the potential paths for self-insured plans that currently cover or exclude Wegovy and Zepbound, the risks of members bypassing the benefit through direct-to-consumer options, and the emerging benchmarks that PBMs will need to address.
For practical guidance on how to engage PBMs now, what concessions and guarantee changes to watch for, and how to prepare your organization for a surge of questions about GLP-1 coverage in early 2026, watch this Truveris pharmacy update.
Watch the GLP-1 Pricing Update Video
